Nd Capital

Plus: Northcott to lead commercial at Nurix, Bach joins Limani Partners and updates from the National MS Society, Octopus and Neurocrine

$300M raise for rare disease company GondolaBio headlines the week’s biggest venture rounds

Plus: Airna, ReviR, LTZ and Synthetica draw Series A cash, while Outpace, Confo and Healx refill their coffers

Swiss biotech Vandria is restoring energy balance in neurons with its first program, soon to enter the clinic for mild cognitive impairment

Plus: Longevity-focused VC debuts and updates from Recode, Merck, Taysha and Paratek 

Plus: Appeals court restricts mifepristone access and updates for Lightcast, AbbVie, Regeneron, Selecta, the IRA

Takeaways from Bio€quity Europe on the latest BioCentury This Week

New CEO moves embattled Belgian biotech into cell therapies, mAbs for cancer

With other investors failing to see product opportunity, VC parlays small bet into ‘brilliant’ return with Galapagos takeout

The 19 newcos are pushing the modality’s frontiers: tapping new cell types, reaching beyond blood cancers and rethinking manufacturing